Results 231 to 240 of about 5,214,305 (354)

Early metastasis is characterized by Gr1+ cell dysregulation and is inhibited by immunomodulatory nanoparticles

Molecular Oncology, EarlyView.
Breast cancer metastasis is associated with myeloid cell dysregulation and the lung‐specific accumulation of tumor‐supportive Gr1+ cells. Gr1+ cells support metastasis, in part, through a CHI3L1‐mediated mechanism, which can be targeted and inhibited with cargo‐free, polymeric nanoparticles.
Jeffrey A. Ma, Sophia M. Orbach, Kate V. Griffin, Kathryn Kang, Yining Zhang, Rebecca S. Pereles, Ian A. Schrack, Guillermo Escalona, Jacqueline S. Jeruss, Lonnie D. Shea   +9 more
wiley   +1 more source

“Complement-ary” Therapies for Age-Related Macular Degeneration

Ophthalmology Science, 2022
Jonathan B. Lin, MD, PhD, Rajendra S. Apte, MD, PhD   +1 more
doaj  

Revisiting Therapeutic Strategies for H. pylori Treatment in the Context of Antibiotic Resistance: Focus on Alternative and Complementary Therapies. [PDF]

Molecules, 2021
Cardos IA, Zaha DC, Sindhu RK, Cavalu S.
europepmc   +1 more source

The Effects of an Educational Intervention on Oncology Nurses' Attitude, Perceived Knowledge, and Self-Reported Application of Complementary Therapies [PDF]

, 2004
Rusti E. Hessig, Lori L. Arcand, Marlene H. Frost   +2 more
openalex   +1 more source

Natural products and complementary therapies for chemotherapy-induced peripheral neuropathy: A systematic review.

Critical reviews in oncology/hematology, 2016
C. Brami, T. Bao, G. Deng
semanticscholar   +1 more source

Detecting homologous recombination deficiency for breast cancer through integrative analysis of genomic data

Molecular Oncology, EarlyView.
This study develops a semi‐supervised classifier integrating multi‐genomic data (1404 training/5893 validation samples) to improve homologous recombination deficiency (HRD) detection in breast cancer. Our method demonstrates prognostic value and predicts chemotherapy/PARP inhibitor sensitivity in HRD+ tumours.
Rong Zhu, Katherine Eason, Suet‐Feung Chin, Paul A. W. Edwards, Raquel Manzano Garcia, Richard Moulange, Jia Wern Pan, Soo Hwang Teo, Sach Mukherjee, Maurizio Callari, Carlos Caldas, Stephen‐John Sammut, Oscar M. Rueda   +12 more
wiley   +1 more source

Complementary and Alternative Therapies for Cancer [PDF]

, 2004
Barrie R. Cassileth, Gary Deng
openalex   +1 more source

Evaluation of KRAS and NRAS mutations in metastatic colorectal cancer: an 8‐year study of 10 754 patients in Turkey

Molecular Oncology, EarlyView.
This nationwide study evaluated KRAS and NRAS mutations in 10 754 Turkish patients with metastatic colorectal cancer. The results revealed a mutation frequency of 51.1%, with 46.6% having KRAS mutations, 4.5% having NRAS mutations, and 48.5% being wild‐type for both.
Gozde Kavgaci, Izzet Akiva, Yavuz Hakan Ozon, Hakan Berkil, Huseyin Karadayi, Omer Dizdar, Suayib Yalcin   +6 more
wiley   +1 more source

Beyond Conventional Treatments: The Role of Complementary Therapies in Head and Neck Cancer. [PDF]

Cancers (Basel)
Verro B, Fiumara S, Saraniti G, Ottoveggio G, Saraniti C.   +4 more
europepmc   +1 more source

Mind-Body Interventions as Alternative and Complementary Therapies for Psoriasis: A Systematic Review of the English Literature. [PDF]

Medicina (Kaunas), 2021
Timis TL, Florian IA, Florian IA, Mitrea DR, Orasan R.   +4 more
europepmc   +1 more source